Meller, Birgit

[["dc.bibliographiccitation.firstpage","223"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","227"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Siggelkow, Heide"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Oezerden, M. M."],["dc.contributor.author","Braune, I."],["dc.contributor.author","Kluge, G."],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:14:40Z"],["dc.date.available","2018-11-07T09:14:40Z"],["dc.date.issued","2012"],["dc.description.abstract","The prevalence of cervical lymphadenopathy in autoimmune thyroiditis (AIT) patients is actually unknown. The aim of the study was the detailed retrospective evaluation of 6 index-patients with lymphadenopathy in Robbins level VI and a prospective study with high resolution ultrasound of lymphadenopathy in All patients compared with controls in all compartments of the neck, accessible to sonographic evaluation. Patients, methods: The retrospective study comprises six patients with AIT, evaluated for enlarged Robbins level VI-LN. We report the findings of fine-needle aspiration Cytology, clonal analysis, histology, and serological testing. The prospective study evaluated the prevalence of lymphadenopathy in 49 consecutive patients with AIT (group 1) and 49 consecutive patients with normal thyroids or nontoxic goiter (group2). Results: In the retrospective study, cytology of paratracheal LN revealed reactive lymphoid hyperplasia in 5/6 of the cases and a centroblastic lymphoma in one patient. The presence of monoclonal lymphatic cells was excluded in 5/6 patients and proven in 1/6 patients. Actual viral-infections were ruled out. In the prospective study All-patients showed significantly more enlarged LN in Robbins level II-IV and VI compared to controls. We found no correlation between lymphadenopathy, age, thyroid volume and nodularity, or autoantibody levels. During follow-up in 34 group 1-patients, lymphadenopathy remained stable in 28 patients, and decreased in 6 patients. Conclusion: Lymphadenopathy in Robbins level II-IV and VI is common in AIT-patients and most probably related to the autoimmune process."],["dc.identifier.doi","10.3413/Nukmed-0484-12-03"],["dc.identifier.isi","000312613800004"],["dc.identifier.pmid","23042429"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27472"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Patients with autoimmune thyroiditis Prevalence of benign lymphadenopathy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","242"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","249"],["dc.bibliographiccitation.volume","55"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten"],["dc.contributor.author","Ritter, Carsten"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Braune, Isabell"],["dc.date.accessioned","2018-11-07T10:19:48Z"],["dc.date.available","2018-11-07T10:19:48Z"],["dc.date.issued","2016"],["dc.description.abstract","The diagnostic strategy in patients with fever or inflammation of unknown origin remains a major clinical challenge. The aim of this study was to evaluate the role of F-18-FDG-PET/CT in patients with unexplained elevated C-reactive protein with or without fever. Contribution of F-18-FDG-PET/CT to the final diagnosis was evaluated. In addition we determined whether a differentiation between patients with or without fever is clinically reasonable. Patients, methods: We retrospectively analysed 72 consecutive patients with unexplained elevated C-reactive protein levels (above 8mg/l) that underwent F-18-FDG-PET/ CT in our facility between 10/2009 and 11/2012. 18F-FDG-PET/CT was considered a so-called diagnostic scan when results decisively led to a final diagnosis and adequate therapy with a response of symptoms was initiated due to the PET/CT result. Results: In 60/72 patients (83%) a final diagnosis was established. Diagnoses included infections (58%), non-infectious inflammatory diseases (29%) and malignancies (8%). F-18-FDG-PET/CT was true positive in 47 cases (65%) and the diagnostic scan in 29 patients (40%). Sensitivity of 18F-FDG-PET/CT was 81% and specificity was 86%. Diagnostics, final diagnoses, F-18-FDG-PET/CT results, SUVmax, C-reactive protein levels and the diagnostic scan did not differ significantly between patients with fever and patients without fever. Conclusion: F-18-FDG-PET/CT is a useful method in the diagnostic workup of patients with inflammation of unknown origin. In our series there was no significant difference between patients with or without fever. Regarding F-18-FDG-PET/CTimaging inflammation of unknown origin and unexplained fever can be joined to one entity."],["dc.identifier.doi","10.3413/Nukmed-0798-16-02"],["dc.identifier.eissn","2567-6407"],["dc.identifier.isi","000389621900006"],["dc.identifier.issn","0029-5566"],["dc.identifier.pmid","27617327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41740"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0029-5566"],["dc.title","F-18-FDG-PET/CT in unexplained elevated inflammatory markers"],["dc.title.alternative","Joining entities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","638"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Cancer"],["dc.bibliographiccitation.lastpage","649"],["dc.bibliographiccitation.volume","123"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Niessner, Martin"],["dc.contributor.author","Dyczkowski, Jerzy"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T10:27:25Z"],["dc.date.available","2018-11-07T10:27:25Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: In previous work, a single administration of anticarcinoembryonic antigen (anti-CEA) I-131-labetuzumab radioimmunotherapy (RIT) after complete resection of colorectal liver metastases was well tolerated and significantly improved survival compared with controls. In the current phase 2 trial, the authors studied repeated RIT in the same setting, examining safety, feasibility, and efficacy. METHODS: Sixty-three patients (median age, 64.5 years) received RIT at 40 to 50 millicuries/m(2) per dose. Before the receipt of RIT, restaging was performed with computed tomography/magnetic resonance imaging and 18 F-fluorodeoxyglucose-positron emission to confirm that patients were \"truly adjuvant.\" Patients who had elevated serum CEA levels or radiographically inconclusive new lesions were classified as \"possibly nonadjuvant,\" but they also received RIT. Time to progression (TTP), overall survival (OS), and cause-specific survival (CSS) were calculated. The median follow-up was 54 months. RESULTS: After the first course of RIT, 14 of 63 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity; 19 patients did not receive the second course of RIT because of impaired performance status (N=5) or relapse (N=14). After the second course of RIT, 9 of 44 patients experienced National Cancer Institute Common Toxicity Criteria grade 4 hematotoxicity. Five patients developed myelodysplastic syndrome (MDS) from 22 to 55 months after their last RIT. The median TTP, OS, and CSS for all patients were 16, 55, and 60 months, respectively. The \"truly adjuvant\" patients (N=39) had an improved median TTP (not reached vs 6.1 months; hazard ratio, 0.12; P<.001), OS (75.6 vs 33.4 months; hazard ratio, 0.44; P=.014), and CSS (not reached vs 41.4 months; hazard ratio, 0.42; P=.014) compared with \" possibly nonadjuvant\" patients (N=24). CONCLUSIONS: Repeated RIT with I-131-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for \"truly adjuvant\" patients. However, the maximum safe dose of I-131-labetuzumab is a single administration of 50 millicuries/m(2). (C) 2016 American Cancer Society."],["dc.description.sponsorship","University Medical Center Goettingen"],["dc.identifier.doi","10.1002/cncr.30390"],["dc.identifier.isi","000396841300015"],["dc.identifier.pmid","27763687"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43229"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","459"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Braz J Urol"],["dc.bibliographiccitation.lastpage","467"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-06-01T10:48:28Z"],["dc.date.available","2021-06-01T10:48:28Z"],["dc.date.issued","2019"],["dc.description.abstract","Purpose: 68Ga-PSMA PET/CT imaging is a promising modality for the staging of recurrent prostate cancer (PCa). Current evidence suggests limited diagnostic value of the 68Ga-PSMA PET/CT in PSA-levels ≤0.3ng/mL. Experimental data have demonstrated an increase in PSMA-expression in PCa metastases by androgen deprivation in vitro. The aim of the current study was to investigate a possible enhancing effect of PSMA with low-dose androgen deprivation in patients with BCR and low PSA-levels. Materials and Methods: Five patients with PCa and BCR, following radical prostatectomy, underwent 68Ga-PSMA PET/CT. A consecutive 68Ga-PSMA PET/CT was performed 6 to 11 days after injection of 80mg of Degarelix (Firmagon®). We recorded PSA and testosterone serum-levels and changes of PSMA-uptake in 68Ga-PSMA PET/CT images. Results: Median PSA prior 68Ga-PSMA PET/CT was 0.27ng/mL. All patients had a decrease in testosterone serum levels from median 2.95μg/l to 0.16μg/l following Degarelix injection. We observed an increase in the standardized uptake value (SUV) in PSMA-positive lymphogenous and osseous lesions in two patients following androgen deprivation. In another two patients, no PSMA positive signals were detected in either the first or the second scan. Conclusion: Our preliminary results of this feasibility assessment indicate a possible enhancing effect of PSMA-imaging induced by low-dose ADT. Despite several limitations and the small number of patients, this could be a new approach to improve staging by 68Ga-PSMA PET/CT in PCa patients with BCR after primary therapy. Further prospective studies with larger number of patients are needed to validate our findings."],["dc.identifier.doi","10.1590/s1677-5538.ibju.2018.0305"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85949"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","final"],["dc.relation.eissn","1677-6119"],["dc.relation.issn","1677-5538"],["dc.title","Enhancing PSMA-uptake with androgen deprivation therapy – a new way to detect prostate cancer metastases?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","198"],["dc.bibliographiccitation.issue","05"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","203"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Bouter, Yvonne"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten"],["dc.contributor.author","Wolf, Bettina"],["dc.contributor.author","Langer, Laura"],["dc.contributor.author","Bankstahl, Jens"],["dc.contributor.author","Wester, Hans"],["dc.contributor.author","Kropf, Saskia"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Bouter, Caroline"],["dc.date.accessioned","2020-12-10T18:47:26Z"],["dc.date.available","2020-12-10T18:47:26Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3413/Nukmed-0971-18-04"],["dc.identifier.eissn","2567-6407"],["dc.identifier.issn","0029-5566"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78765"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT"],["dc.title.alternative","Der immunhistochemische Nachweis CXCR4-exprimierender Lymphozyten bei chronischer Osteomyelitis bestätigt einen spezifischen Uptake in der 68Ga-Pentixafor-PET/CT"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T11:24:50Z"],["dc.date.available","2018-11-07T11:24:50Z"],["dc.date.issued","2009"],["dc.format.extent","S404"],["dc.identifier.isi","000208690802128"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56493"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Labelling of the bispecific trivalent monoclonal antibody TF2 and the TF2 binding hapten IMP288 for in vitro and in vivo investigations in colorectal cancer (Immuno SPET, PET and radioimmuno therapy)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Sharkey, R. M."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T08:51:26Z"],["dc.date.available","2018-11-07T08:51:26Z"],["dc.date.issued","2011"],["dc.format.extent","S243"],["dc.identifier.isi","000208619400553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21933"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Automatized Ga-68-Labeling of the Hapten-Peptide, IMP288, for Radioimmuno-PET Trials to Evaluate Therapeutic Response"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","7441"],["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Bioorganic & Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","7448"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Zuhayra, M."],["dc.contributor.author","Alfteimi, A."],["dc.contributor.author","von Forstner, C."],["dc.contributor.author","Luetzen, U."],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Henze, Elvira"],["dc.date.accessioned","2018-11-07T11:22:27Z"],["dc.date.available","2018-11-07T11:22:27Z"],["dc.date.issued","2009"],["dc.description.abstract","O-(2-[F-18]fluoroethyl)-L-tyrosine ([(18)]FET) is one of the first F-18-labeled amino acids for imaging amino acid metabolism in tumors. This tracer overcomes the disadvantages of [F-18]fluorodeoxyglucose, [F-18]FDG, and [C-11]methionine, [C-11]MET. Nevertheless, the various synthetic methods providing F-18[FET]exhibit a big disadvantage concerning the necessity of two purification steps during the synthesis including HPLC purification, which causes difficulties in the automation, moderate yields, and long synthesis times >60 min. A new approach for the synthesis of [F-18]FET is developed starting from 2-bromoethyl triflate as precursor. After optimization of the synthesis parameters including the distillation step of [F-18]-FCH2CH2Br combined with the final purification of [F-18]FET using a simple solid phase extraction instead of an HPLC run the synthesis [F-18]FET could be significantly simplified, shortened, and improved. The radiochemical yield (RCY) was about 45% (not decay corrected and calculated relative to [F-18]F activity that was delivered from the cyclotron). Synthesis time was only 35 min from the end of bombardment (EOB) and the radiochemical purity was >99% at the end of synthesis (EOS). Thus, this simplified synthesis for [F-18]FET offers a very good option for routine clinical use. (C) 2009 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.bmc.2009.09.029"],["dc.identifier.isi","000270903100005"],["dc.identifier.pmid","19804977"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55994"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0968-0896"],["dc.title","New approach for the synthesis of [F-18]fluoroethyltyrosine for cancer imaging: Simple, fast, and high yielding automated synthesis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1226"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1231"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Rades, Dirk"],["dc.contributor.author","Wolff, Christian"],["dc.contributor.author","Nadrowitz, Roger"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Schild, Steven E."],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T11:22:04Z"],["dc.date.available","2018-11-07T11:22:04Z"],["dc.date.issued","2009"],["dc.description.abstract","Purpose: Systemic therapies when added to whole brain radiotherapy have failed to improve the survival of patient h multiple brain metastases. The epidermal growth factor receptor antibody cetuximab is an attractive option, if it is able to cross the blood-brain barrier. This might be proven with molecular imaging if the radiolabeled antibody is stable long enough to be effective. This study investigated the stability of radiolabeled cetuximab (Erbitux) ((131)I-Erbi) and potential synergistic effects with radiotherapy in vitro. Methods and Materials: Two cell lines were investigated, A431 with numerous epidermal growth factor receptors, and JIMT without epidermal growth factor receptors. We labeled 0.4 mg cetuximab with 50 MBq of [(131)I] iodide. Stability was determined for 72 h. The cell cultures were incubated with (131)I-Erbi or cold cetuximab for 72 h. Uptake and cell proliferation were measured every 24 h after no radiotherapy or irradiation with 2, 4, or 10 Gy. Results: The radiolabeling yield of (131)I-Erbi was always >80%. The radiochemical purity was still 93.6% after 72 h. A431 cells showed a (131)I-Erbi uptake about 100-fold greater than the JIMT controls. After 48 h, the A431 cultures showed significantly decreased proliferation. At 72 h after irradiation, (131)I-Erbi resulted in more pronounced inhibition of cell proliferation than the cold antibody in all radiation dose groups. Conclusion: (131)I-Erbi was stable for <= 72 h. Radiotherapy led to increased tumor cell uptake of (131)I-Erbi. Radiotherapy and (131)I-Erbi synergistically inhibited tumor cell proliferation. These results provide the prerequisite data for a planned in vivo study of whole brain radiotherapy plus cetuximab for brain metastases. (C) 2009 Elsevier Inc."],["dc.description.sponsorship","German Research Society (DFG) [KFO 179]"],["dc.identifier.doi","10.1016/j.ijrobp.2008.12.029"],["dc.identifier.isi","000271489600040"],["dc.identifier.pmid","19356858"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55918"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0360-3016"],["dc.title","RADIOACTIVE EGFR ANTIBODY CETUXIMAB IN MULTIMODAL CANCER TREATMENT: STABILITY AND SYNERGISTIC EFFECTS WITH RADIOTHERAPY"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Flaemig, L."],["dc.contributor.author","Bache, M."],["dc.contributor.author","Odparlik, A."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Vordermark, Dirk"],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:19:16Z"],["dc.date.available","2018-11-07T09:19:16Z"],["dc.date.issued","2013"],["dc.format.extent","S160"],["dc.identifier.isi","000325853400198"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28594"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)"],["dc.relation.eventlocation","Lyon, FRANCE"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Biological effects of positron emitters in thyroid cell cultures"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]